Analyst Price Targets — DTIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 9, 2026 10:52 am | — | Oppenheimer | $20.00 | $6.77 | TheFly | Precision BioSciences initiated with an Outperform at Oppenheimer |
| March 13, 2026 6:57 pm | Maury Raycroft | Jefferies | $19.00 | $5.67 | StreetInsider | Precision BioSciences Inc. (DTIL) PT Lowered to $19 at Jefferies, but 'near-term setup is attractive' |
| April 1, 2024 7:19 am | Justin Zelin | BTIG | $30.00 | $13.56 | TheFly | Precision BioSciences price target raised to $30 from $2 at BTIG |
| November 10, 2022 10:11 am | — | Goldman Sachs | $1.00 | $1.38 | Benzinga | Goldman Sachs Maintains Neutral on Precision BioSciences, Lowers Price Target to $1 |
Latest News for DTIL
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision…
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000® Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions published by FTSE…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DTIL.
U.S. House Trading
No House trades found for DTIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.